skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 52,979  for All Library Resources

Sorted by: Sorted by: TitleOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Database: Free E- Journals remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
01 Glucocorticoids for SLE: what are the current questions and issues?
01 Glucocorticoids for SLE: what are the current questions and issues?
Material Type:
Article 		Add to My Research

01 Glucocorticoids for SLE: what are the current questions and issues?

Lupus science & medicine, 2022-04, Vol.9 (Suppl 1), p.A1-A1 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2022-la.1

Full text available

Citations Cited by
2
01 Should we vaccinate all SLE patients against papillomavirus and herpes zoster?
01 Should we vaccinate all SLE patients against papillomavirus and herpes zoster?
Material Type:
Article 		Add to My Research

01 Should we vaccinate all SLE patients against papillomavirus and herpes zoster?

Lupus science & medicine, 2021-04, Vol.8 (Suppl 1), p.A1-A1 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-la.1

Full text available

Citations Cited by
3
02 Cyclophosphamide: what is its role in the treatment of lupus nephritis and the new treatment paradigm?
02 Cyclophosphamide: what is its role in the treatment of lupus nephritis and the new treatment paradigm?
Material Type:
Article 		Add to My Research

02 Cyclophosphamide: what is its role in the treatment of lupus nephritis and the new treatment paradigm?

Lupus science & medicine, 2022-04, Vol.9 (Suppl 1), p.A1-A2 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2022-la.2

Full text available

Citations Cited by
4
02 Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity
02 Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity
Material Type:
Article 		Add to My Research

02 Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity

Lupus science & medicine, 2021-04, Vol.8 (Suppl 1), p.A1-A2 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-la.2

Full text available

Citations Cited by
5
03 Debate: a minority of lupus patients (will) need a biologic
03 Debate: a minority of lupus patients (will) need a biologic
Material Type:
Article 		Add to My Research

03 Debate: a minority of lupus patients (will) need a biologic

Lupus science & medicine, 2020-09, Vol.7 (Suppl 2), p.A2-A2 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2020-la.3

Digital Resources/Online E-Resources

Citations Cited by
6
07 Lessons from transplantation: Multitargeted therapy for proliferative lupus nephritis
07 Lessons from transplantation: Multitargeted therapy for proliferative lupus nephritis
Material Type:
Article 		Add to My Research

07 Lessons from transplantation: Multitargeted therapy for proliferative lupus nephritis

Lupus science & medicine, 2021-04, Vol.8 (Suppl 1), p.A4-A4 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-la.7

Full text available

Citations Cited by
7
08 Lessons from ITP: treatment of refractory thrombocytopenia
08 Lessons from ITP: treatment of refractory thrombocytopenia
Material Type:
Article 		Add to My Research

08 Lessons from ITP: treatment of refractory thrombocytopenia

Lupus science & medicine, 2021-04, Vol.8 (Suppl 1), p.A4-A5 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-la.8

Full text available

Citations Cited by
8
09 Herpes zoster prevalence and recommendations from clinical trial safety data
09 Herpes zoster prevalence and recommendations from clinical trial safety data
Material Type:
Article 		Add to My Research

09 Herpes zoster prevalence and recommendations from clinical trial safety data

Lupus science & medicine, 2023-09, Vol.10 (Suppl 2), p.A5-A6 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2023-la.9

Full text available

Citations Cited by
9
1 ,25-Dihydroxyvitamin D (calcitriol) and its analogue, 19-nor-1 ,25(OH) D , potentiate the effects of ionising radiation on human prostate cancer cells
1 ,25-Dihydroxyvitamin D (calcitriol) and its analogue, 19-nor-1 ,25(OH) D , potentiate the effects of ionising radiation on human prostate cancer cells
Material Type:
Article 		Add to My Research

1 ,25-Dihydroxyvitamin D (calcitriol) and its analogue, 19-nor-1 ,25(OH) D , potentiate the effects of ionising radiation on human prostate cancer cells

British journal of cancer, 2003-08, Vol.89 (4), p.746-753 [Peer Reviewed Journal]

ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/sj.bjc.6601161

Full text available

Citations Cited by
10
1-Acetyl-2-phenylhydrazine carcinogenesis in mice
1-Acetyl-2-phenylhydrazine carcinogenesis in mice
Material Type:
Article 		Add to My Research

1-Acetyl-2-phenylhydrazine carcinogenesis in mice

British journal of cancer, 1979-05, Vol.39 (5), p.584-587 [Peer Reviewed Journal]

ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.1979.105 ;PMID: 486314

Full text available

Citations Cited by
11
1-color-avoiding paths, special tournaments, and incidence geometry
1-color-avoiding paths, special tournaments, and incidence geometry
Material Type:
Article 		Add to My Research

1-color-avoiding paths, special tournaments, and incidence geometry

arXiv.org, 2016-09

2016. This work is published under http://arxiv.org/licenses/nonexclusive-distrib/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;http://arxiv.org/licenses/nonexclusive-distrib/1.0 ;EISSN: 2331-8422 ;DOI: 10.48550/arxiv.1608.04153

Full text available

Citations Cited by
12
1 in 3 adults could have diabetes by 2050
1 in 3 adults could have diabetes by 2050
Material Type:
magazinearticle 		Add to My Research

1 in 3 adults could have diabetes by 2050

Managed care, 2010-11, Vol.19 (11), p.47-47

ISSN: 1062-3388 ;PMID: 21141380

Full text available

Citations Cited by
13
1. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010: Introduction
1. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010: Introduction
Material Type:
Article 		Add to My Research

1. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010: Introduction

British journal of cancer, 2011-12, Vol.105 (S2), p.S2-S5 [Peer Reviewed Journal]

Copyright © 2011 Cancer Research UK 2011 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2011.474 ;PMID: 22158314

Full text available

Citations Cited by
14
1. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010: The Fraction of Cancer Attributable to Lifestyle and Environmental Factors in the UK in 2010
1. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010: The Fraction of Cancer Attributable to Lifestyle and Environmental Factors in the UK in 2010
Material Type:
Article 		Add to My Research

1. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010: The Fraction of Cancer Attributable to Lifestyle and Environmental Factors in the UK in 2010

British journal of cancer, 2011-12, Vol.105 (S2), p.S2-S5 [Peer Reviewed Journal]

2015 INIST-CNRS ;Copyright Nature Publishing Group Dec 6, 2011 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2011.474 ;PMID: 22158314 ;CODEN: BJCAAI

Full text available

Citations Cited by
15
10. Cancers attributable to exposure to hormones in the UK in 2010
10. Cancers attributable to exposure to hormones in the UK in 2010
Material Type:
Article 		Add to My Research

10. Cancers attributable to exposure to hormones in the UK in 2010

British journal of cancer, 2011-12, Vol.105 Suppl 2 (S2), p.S42-S48 [Peer Reviewed Journal]

Copyright Nature Publishing Group Dec 6, 2011 ;Copyright © 2011 Cancer Research UK 2011 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2011.483 ;PMID: 22158320 ;CODEN: BJCAAI

Full text available

Citations Cited by
16
10 IT certifications paying the highest premiums today
10 IT certifications paying the highest premiums today
Material Type:
Article 		Add to My Research

10 IT certifications paying the highest premiums today

CIO, 2022-12

Copyright Foundry Dec 29, 2022 ;ISSN: 0894-9301

Full text available

Citations Cited by
17
10 life-threatening behavior myths
10 life-threatening behavior myths
Material Type:
Article 		Add to My Research

10 life-threatening behavior myths

Veterinary medicine (1985), 2008-09, Vol.103 (9), p.504-506 [Peer Reviewed Journal]

Copyright Advanstar Communications, Inc. Sep 2008 ;ISSN: 8750-7943 ;EISSN: 1939-1919

Full text available

Citations Cited by
18
10 life-threatening behavior myths Have some of your clients--or even you--voiced any of these misconceptions? Think about your responses to colleagues and clients who perpetuate these myths. Your words can be the best medicine for preventing relinquishments and euthanasia and bonding clients to your practice
10 life-threatening behavior myths Have some of your clients--or even you--voiced any of these misconceptions? Think about your responses to colleagues and clients who perpetuate these myths. Your words can be the best medicine for preventing relinquishments and euthanasia and bonding clients to your practice
Material Type:
Article 		Add to My Research

10 life-threatening behavior myths Have some of your clients--or even you--voiced any of these misconceptions? Think about your responses to colleagues and clients who perpetuate these myths. Your words can be the best medicine for preventing relinquishments and euthanasia and bonding clients to your practice

Veterinary medicine (1985), 2008-09, Vol.103 (9), p.504 [Peer Reviewed Journal]

COPYRIGHT 2008 Intellisphere, LLC ;ISSN: 8750-7943 ;EISSN: 1939-1919

Full text available

Citations Cited by
19
10 most important contemporary challenges in the management of SLE
10 most important contemporary challenges in the management of SLE
Material Type:
Article 		Add to My Research

10 most important contemporary challenges in the management of SLE

Lupus science & medicine, 2019-01, Vol.6 (1), p.e000303-e000303 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 2053-8790 ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2018-000303 ;PMID: 30729019

Full text available

Citations Cited by
20
10 soldiers lightly wounded in arson attack at army base. Police believe Arab youth threw firecrackers at J'lem's Oferit base
10 soldiers lightly wounded in arson attack at army base. Police believe Arab youth threw firecrackers at J'lem's Oferit base
Material Type:
Newspaper Article 		Add to My Research

10 soldiers lightly wounded in arson attack at army base. Police believe Arab youth threw firecrackers at J'lem's Oferit base

The Jerusalem post, 2012-06-18

Copyright 2012 The Jerusalem Post

Digital Resources/Online E-Resources

Citations Cited by

Results 1 - 20 of 52,979  for All Library Resources

Sorted by: Sorted by: TitleOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1961  (775)
  2. 1961 To 1976  (1,388)
  3. 1977 To 1992  (3,141)
  4. 1993 To 2009  (16,236)
  5. After 2009  (31,441)
  6. More options open sub menu

Subject 

  1. Science & Technology  (23,288)
  2. Life Sciences & Biomedicine  (21,092)
  3. Humans  (17,871)
  4. Female  (11,771)
  5. Oncology  (9,997)
  6. Male  (9,882)
  7. Middle Aged  (7,781)
  8. Adult  (7,202)
  9. Aged  (6,141)
  10. Biological And Medical Sciences  (5,744)
  11. Medical Sciences  (5,507)
  12. Tumors  (4,326)
  13. Risk Factors  (4,101)
  14. Incidence  (3,980)
  15. Animals  (2,975)
  16. Adolescent  (2,588)
  17. Patients  (2,356)
  18. Epidemiology  (2,284)
  19. Cardiovascular System & Cardiology  (2,138)
  20. Aged, 80 And Over  (2,104)
  21. More options open sub menu

Language 

  1. English  (50,803)
  2. Japanese  (3,150)
  3. Korean  (821)
  4. French  (775)
  5. Spanish  (452)
  6. Portuguese  (146)
  7. Russian  (76)
  8. Dutch  (59)
  9. Chinese  (42)
  10. German  (40)
  11. Turkish  (31)
  12. Norwegian  (28)
  13. Arabic  (21)
  14. Danish  (10)
  15. Catalan  (7)
  16. Czech  (2)
  17. Italian  (2)
  18. Afrikaans  (2)
  19. Polish  (1)
  20. BokmÃ¥l, Norwegian  (1)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait